Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ocshner HMO limiting Claritin scripts to 10 days of therapy under antihistamine guidelines.

Executive Summary

OCSHNER HEALTH PLAN CLARITIN SCRIPTS LIMITED TO 10 DAYS OF THERAPY per month under guidelines the Metairie, La. HMO is implementing for antihistamine therapies used by its patients, VP-Pharmacy Services Daniel Lewis told the American Society of Health-System Pharmacists' mid-year clinical meeting Dec. 11 in New Orleans. Schering-Plough's Claritin is covered as third-line therapy by Ocshner. Patients on the once-daily version of Claritin (loratadine) are allowed 10 pills, while patients on twice-daily Claritin D (loratadine plus pseudoephedrine) can have 20, Lewis said.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel